Innostellar Biotherapeutics Co.,ltd

This study tests a gene therapy called LX101 for people with a rare inherited eye disease that causes blindness. 30 participants aged 6 and older were randomly assigned to receive the therapy or no treatment. The goal is to see if the treatment improves functional vision and ligh…

This early-stage study tests a gene therapy called LX101 for people with a rare inherited eye disease that causes vision loss. The therapy uses a harmless virus to deliver a working copy of the RPE65 gene to the retina. Nine participants aged 6 and older will be monitored for saf…

This study tests a new gene therapy called LX102 for people with wet age-related macular degeneration (nAMD), a common cause of vision loss. About 50 adults aged 50 to 89 who have already responded to standard anti-VEGF injections will receive the treatment. The goal is to see if…